Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Charles River Laboratories Intl (CRL)

Charles River Laboratories Intl (CRL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,803,496
  • Shares Outstanding, K 48,839
  • Annual Sales, $ 2,266 M
  • Annual Income, $ 226,370 K
  • 60-Month Beta 1.11
  • Price/Sales 3.12
  • Price/Cash Flow 16.87
  • Price/Book 5.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.83
  • Number of Estimates 8
  • High Estimate 1.85
  • Low Estimate 1.82
  • Prior Year 1.49
  • Growth Rate Est. (year over year) +22.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.74 +8.89%
on 12/18/19
161.39 -1.00%
on 01/14/20
+10.88 (+7.31%)
since 12/17/19
3-Month
125.39 +27.43%
on 10/24/19
161.39 -1.00%
on 01/14/20
+23.71 (+17.42%)
since 10/17/19
52-Week
116.24 +37.46%
on 01/23/19
161.39 -1.00%
on 01/14/20
+41.33 (+34.89%)
since 01/17/19

Most Recent Stories

More News
Icon PLC (ICLR) Hits Fresh High: Is There Still Room to Run?

Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ICLR : 175.78 (+0.38%)
CHE : 473.83 (+0.12%)
CRL : 159.78 (-0.11%)
PINC : 36.77 (-0.73%)
Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Fios Genomics, a leading provider of bioinformatics data analysis services....

CRL : 159.78 (-0.11%)
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CRL : 159.78 (-0.11%)
Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates

Charles River (NYSE: CRL) today announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited ("Takeda"). Together, Charles River and Takeda will launch multiple integrated...

CRL : 159.78 (-0.11%)
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14th,...

JPM : 138.20 (+0.69%)
CRL : 159.78 (-0.11%)
Charles River (CRL) Soars to 52-Week High, Time to Cash Out?

Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CRL : 159.78 (-0.11%)
Charles River Laboratories Completes the Acquisition of HemaCare Corporation

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million...

CRL : 159.78 (-0.11%)
HEMA : 25.3100 (+0.60%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates HemaCare Corporation

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of HemaCare Corporation ("HemaCare" or the "Company") (OTCMKTS: HEMA) in connection...

HEMA : 25.3100 (+0.60%)
CRL : 159.78 (-0.11%)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HemaCare Corporation

Rowley Law PLLC is investigating potential securities law violations by HemaCare Corporation (OTCMKTS: HEMA) and its board of directors concerning the proposed acquisition of the company by Charles River...

HEMA : 25.3100 (+0.60%)
CRL : 159.78 (-0.11%)
HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HEMA and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of HemaCare Corporation (Other OTC: HEMA) breached their fiduciary...

CRL : 159.78 (-0.11%)
HEMA : 25.3100 (+0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CRL with:

Business Summary

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused...

See More

Key Turning Points

2nd Resistance Point 162.33
1st Resistance Point 161.05
Last Price 159.78
1st Support Level 158.29
2nd Support Level 156.80

See More

52-Week High 161.39
Last Price 159.78
Fibonacci 61.8% 144.14
Fibonacci 50% 138.82
Fibonacci 38.2% 133.49
52-Week Low 116.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar